Globus Medical (GMED)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$78.29+0.22%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Revenue growth to at least $3.18B in FY26: FY26 revenue guidance $3.18B-$3.22B vs $3.18B target.
Globus Medical grows revenue about 6% yearly, with $3.2B expected in 2026. Profit margins improve, shown by operating income rising from $97M to $150M in one year. Net income also grew strongly to $124M in Q1 2026. The company has stable management and a fair valuation below peers.
The stock is selling off with an 18.6% drop from its high. Growth could slow below analyst expectations of 6.5%. Profit gains may stall if cost control weakens or market demand softens.
The price is about 32% below our fair value near $115, reflecting cautious sentiment. Analysts expect 6.5% revenue growth, which we broadly agree with, but recent selling pressures add risk.
Breaks if: EPS guidance cut below $4.5 for FY26
Breaks if: Net income falls below $110M in any quarter
Breaks if: Operating income falls below $140M in any quarter
Continue efforts to enhance operating income through cost management and efficiency improvements.
Breaks if: Revenue falls below $3.0B in FY26
Drive top-line growth through share gains, product portfolio expansion, and international market growth.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $598.1 million in 2025-Q1 to $789.6 million in 2026-Q2, a 32.1% increase. US Spine and International Spine segments showed strong growth in 2026-Q2. Management consistently emphasized revenue growth driven by share gains and international expansion, and the financials show delivering trajectory.
“Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro.”
“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings.”
“Momentum built throughout 2025 accelerated in the fourth quarter, capping off a strong finish with double-digit sales growth.”
“We increased guidance for full-year 2025 revenue to be in the range of $2.86 to $2.90 billion.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by robust recent financial performance and a focus on increasing revenue and earnings.
The market appears to price GMED as cheap compared to its peers, with an expectations gap indicating that some positive developments may not be fully recognized. The valuation is justified, suggesting that the current price reflects a reasonable assessment of the company's fundamentals.
Fundamentals are likely to continue improving as management focuses on revenue growth, operating income, and earnings per share. The recent financial performance has been strong, but there is a low probability of a miss, which is notable given the company's history in a high-miss-rate industry.
The long-term thesis hinges on maintaining revenue growth and margin expansion while navigating potential risks such as economic conditions and sector performance. Key forward scenarios include the impact of guidance changes and the performance of sector bellwethers like ABT, MDT, and SYK.
In the next 1 to 3 years, GMED's performance will depend on its ability to sustain growth and manage risks effectively. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports revenue growth and net income. However, analysts trimmed growth views, which threatens the revenue and EPS guidance for 2026.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.